ALK Inhibitors in the Treatment of ALK Positive NSCLC

Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have assembled the evidence related to the efficacy and safety of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad, Lin, Jie, Liao, Guixiang, Tian, Yunhong, Liang, Yingying, Li, Rong, Liu, Mengzhong, Yuan, Yawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333640/
https://www.ncbi.nlm.nih.gov/pubmed/30687633
http://dx.doi.org/10.3389/fonc.2018.00557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333640/
https://www.ncbi.nlm.nih.gov/pubmed/30687633
http://dx.doi.org/10.3389/fonc.2018.00557

Ejemplares similares